Last €18.38 EUR
Change Today -0.02 / -0.11%
Volume 1.4K
AB On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 3:08 AM 05/22/13 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Open
€18.40
Previous Close
€18.40
Day High
€18.40
Day Low
€18.38
52 Week High
10/31/12 - €23.00
52 Week Low
07/13/12 - €9.02
Market Cap
582.1M
Average Volume 10 Days
54.3K
EPS TTM
€-0.34
Shares Outstanding
31.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicine in the United States and Europe. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. Its lead compound is Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company’s pipeline includes three Phase III clinical trials ongoing in pancreatic cancer, GIST, and mastocytosis and eight Phase II clinical trials completed. It markets Masitinib under the brand name Masivet for the veterinary market in Europe. The company’s other tyrosine kinase inhibitors that plan to initiate preclinical development include KIT816 for aggressive mastocytosis, seminoma, and acute myeloid leukemia; VEGFR2 for kidney cancer; and Bcr-Abl/Lyn for chronic myeloid leukemia. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

88 Employees
Last Reported Date: 04/29/13
Founded in 2001

ab science sa (AB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ab science sa (AB) Key Developments

AB Science SA Announces Launch of a Phase 3 Clinical Trial in the Treatment of Alzheimer's Disease with Masitinib

AB Science SA announced the launch of a phase 3 clinical trial in the treatment of Alzheimer's disease with masitinib, as well as the recruitment of the first patients in this study in several countries.  This is an international, multicenter, randomized (1:1:1 ratio), double-blind, placebo controlled, three parallel group phase 3 study to compare the efficacy and safety of masitinib at two different doses in the treatment of patients with mild to moderate Alzheimer's disease. Study treatment will be given as add-on therapy to patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (rivastigmine) and/or memantine, with no changes foreseen in therapy throughout the study. The study aims at evaluating the effect of masitinib after 24 weeks of treatment on cognition and memory assessed by Alzheimer's Disease Assessment Scale (ADAS-Cog) and on self-care and activities of daily living assessed by Alzheimer's Disease Assessment Cooperative Study Activities on Daily Living (ADCS-ADL) at week-24. This study, for which recruitment has started in Europe and other countries, will enroll approximately 400 patients. As a reminder, masitinib is one of the few drugs that have generated significant efficacy results in phase 2 studies. In fact, the phase 3 study follows a phase 2 study, in which masitinib administered as an add-on therapy to standard care during 24 weeks showed promising signs of retarding the rate of cognitive decline of Alzheimer's disease as compared against placebo, with an acceptable tolerance profile. Improvement in cognitive function and functional capacity was seen in the masitinib treatment group, as evident through the sustained and statistically significant response in ADAS-Cog, as well as the mean change in ADAS-Cog and ADCS-ADL values relative to baseline. The phase 2 results have been published: Alzheimers Res Ther. 2011 Apr. 19;3(2):16. doi: 10.1186/alzrt75. The objective of the double-blinded, randomized in parallel groups and placebo-controlled study was to evaluate masitinib, administered orally over 24 weeks, in patients suffering from mild-to-moderate Alzheimer's disease. Response was measured by change in ADAS-Cog, ADAS-ADL and MMSE scores after 24 weeks of treatment. A total of 35 patients were included in this study. The rate of clinically relevant cognitive decline according to the primary endpoint, ADAS-Cog response (increase > 4 points), was significantly lower with masitinib treatment compared to placebo after 12 and 24 weeks (6% versus 50% for both; p=0.040 and p=0.046, respectively). Moreover, whilst the placebo treatment-arm showed worsening mean ADAS-Cog, ADCS-ADL, and MMSE scores, the masitinib treatment-arm reported improvements, with statistical significance between treatment-arms at weeks 12 and/or 24 (respectively, p=0.016 and 0.030; p=0.035 and 0.128; and p=0.047 and 0.031). Adverse events occurred more frequently with masitinib treatment (65% versus 38% of patients); however, the majority of events were mild or moderate and transient.

AB Science S.A. Announces Consolidated Earnings Results for the Year Ended Dec. 31, 2012 and Consolidated Revenue Results for the First Quarter of 2013

AB Science S.A. announced consolidated earnings results for the year ended Dec. 31, 2012 and consolidated revenue results for the first quarter of 2013. Total revenues for the year 2012 amounted to EUR 1,304,000 compared with EUR 1,104,000 in the previous year. Operating loss amounted to EUR 10,613,000 compared with EUR 9,716,000 reported in 2011. Net loss attributable to equity holders of the parent company was EUR 10,985,000 or EUR 0.34 per diluted share against EUR 9,651,000 or EUR 0.31 per diluted share reported last year. Net cash used in operating activities was EUR 324,000 against EUR 433,000 and acquisitions of financial assets was EUR 8,500,000 against EUR 17,000,000 reported last year. AB Science revenues in the first quarter of 2013 amounted to EUR 571,000 versus EUR 321,000 in the first quarter of 2012, up 78%. These revenues derive from the commercial exploitation of masitinib in veterinary medicine in Europe and in the United States.

AB Science S.A.(ENXTPA:AB) added to SBF 120 Index

AB Science S.A. will be added to SBF 120 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €18.38 EUR -0.02

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Oasmia Pharmaceutical AB kr9.85 SEK -0.35
Pfizer Inc $28.78 USD +0.08
View Industry Companies
 

Industry Analysis

AB

Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 432.4x
Price/Book 115.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 389.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.